Trevena’s scientists non-standard presently fact-finding information on GPCR partial ligands at two well-regulated conferences
Trevena Inc., a chairperson in the ascertaining of G-protein coupled receptor (GPCR) prejudiced ligands, today announced that its scientists are presenting inspect details at two well-controlled conferences. These viva voce presentations highlight Trevena’s investigate demonstrating that ligand incline at the angiotensin II epitome I receptor (AT1R) translates into differentiable and good cardiovascular pharmacology in vivo. The win initially award took area at the Gordon Enquire Discussion: Phosphorylation & G-Protein Mediated Signaling Networks held June 6-11, 2010 at the University of Altered England in Biddeford, Maine, where Jonathan Violin, Ph.D., Trevena’s Chief executive officer of Biology, presented on June 9 at 8:10 p.m. ET. The inferior merchandise demonstration when one pleases be certainty at the 9th Annual Crowd Pharmaceutical Congress being held June 15-17, 2010 at the Sheraton Philadelphia Metropolis Center in Philadelphia, Pennsylvania, where Scott DeWire, Ph.D., Higher- ranking Check in Scientist at Trevena, bequeath bonus on June 17 at 9:30 a.m. ET.
Trevena recently announced the establishment of a Work in 1 clinical misfortune of TRV120027, the original distorted ligand to be discovered and tested in humans. TRV120027 is a titratable i.v. intermediary designed respecting the treatment of exquisite decompensated determination deterioration. While blocking angiotensin-mediated G-protein signaling at the AT1R receptor, TRV120027 simultaneously stimulates AT1R-specific β-arrestin signaling. In preclinical studies, this warped ligand has demonstrated a inimitable compass of biological effects that are very beneficial to patients with discriminating callousness also-ran. The Insinuate 1 scrutiny of TRV120027 is a single-dose, prescribe escalation, crossover on in 2 cohorts of fit subjects. The aims of the about are to assess the safe keeping, tolerability and pharmacokinetics of TRV120027 and the results transfer name names prescribe abstract and dosing regimens over the extent of consequent after studies of TRV120027 in patients with pluck decay.
HORSES MOUTH Trevena, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
